Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCARA: Abatacept in Early ACPA+ RA
NCT03492658Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- May 2018
- Primary completion
- Oct 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Percentage of ACPA-expressing B cells that express the marker Ki-67 at 24 weeks. Started May 2018; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03492658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492658.